These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32328797)

  • 21. Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study.
    Swain MG; Ramji A; Patel K; Sebastiani G; Shaheen AA; Tam E; Marotta P; Elkhashab M; Bajaj HS; Estes C; Razavi H
    CMAJ Open; 2020; 8(2):E429-E436. PubMed ID: 32518095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic syndrome, but not non-alcoholic fatty liver disease, increases 10-year mortality: A prospective, community-cohort study.
    Niriella MA; Kasturiratne A; Beddage TU; Withanage SA; Goonatilleke DC; Abeysinghe CP; De Mel RT; Balapitiya TL; De Silva ST; Dassanayake AS; De Silva AP; Pathmeswaran A; Wickramasinghe AR; Kato N; de Silva HJ
    Liver Int; 2020 Jan; 40(1):101-106. PubMed ID: 31472085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease.
    Cotter TG; Rinella M
    Gastroenterology; 2020 May; 158(7):1851-1864. PubMed ID: 32061595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure.
    Valbusa F; Agnoletti D; Scala L; Grillo C; Arduini P; Bonapace S; Calabria S; Scaturro G; Mantovani A; Zoppini G; Turcato E; Maggioni AP; Arcaro G; Targher G
    Int J Cardiol; 2018 Aug; 265():162-168. PubMed ID: 29739707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease.
    Younossi ZM; Henry L
    Pharmacoeconomics; 2015 Dec; 33(12):1245-53. PubMed ID: 26233836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
    Younossi ZM; Blissett D; Blissett R; Henry L; Stepanova M; Younossi Y; Racila A; Hunt S; Beckerman R
    Hepatology; 2016 Nov; 64(5):1577-1586. PubMed ID: 27543837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study.
    Baratta F; Pastori D; Angelico F; Balla A; Paganini AM; Cocomello N; Ferro D; Violi F; Sanyal AJ; Del Ben M
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2324-2331.e4. PubMed ID: 31887443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is explained by metabolic comorbidities.
    Önnerhag K; Dreja K; Nilsson PM; Lindgren S
    Clin Res Hepatol Gastroenterol; 2019 Oct; 43(5):542-550. PubMed ID: 30827925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties.
    Allen AM; Lazarus JV; Younossi ZM
    J Hepatol; 2023 Jul; 79(1):209-217. PubMed ID: 36740046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis.
    Kodama K; Kawaguchi T; Hyogo H; Nakajima T; Ono M; Seike M; Takahashi H; Nozaki Y; Kawanaka M; Tanaka S; Imajo K; Sumida Y; Kamada Y; Fujii H; Seko Y; Takehara T; Itoh Y; Nakajima A; Masaki N; Torimura T; Saibara T; Karino Y; Chayama K; Tokushige K
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1626-1632. PubMed ID: 30668889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The utility of NAFLD fibrosis score for prediction of mortality among patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of cohort study.
    Jaruvongvanich V; Wijarnpreecha K; Ungprasert P
    Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):629-634. PubMed ID: 28716600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated Costs and Healthcare Resource Utilization in Patients With Type 2 Diabetes and Established Cardiovascular Disease in Israel.
    Melzer Cohen C; Hallén N; Chodick G; Bourvine L; Waner T; Karasik A
    Value Health Reg Issues; 2020 Sep; 22():83-92. PubMed ID: 32798839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
    Ekstedt M; Hagström H; Nasr P; Fredrikson M; Stål P; Kechagias S; Hultcrantz R
    Hepatology; 2015 May; 61(5):1547-54. PubMed ID: 25125077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Taylor RS; Taylor RJ; Bayliss S; Hagström H; Nasr P; Schattenberg JM; Ishigami M; Toyoda H; Wai-Sun Wong V; Peleg N; Shlomai A; Sebastiani G; Seko Y; Bhala N; Younossi ZM; Anstee QM; McPherson S; Newsome PN
    Gastroenterology; 2020 May; 158(6):1611-1625.e12. PubMed ID: 32027911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
    Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
    J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA.
    Zou B; Yeo YH; Jeong D; Park H; Sheen E; Lee DH; Henry L; Garcia G; Ingelsson E; Cheung R; Nguyen MH
    Dig Dis Sci; 2020 May; 65(5):1520-1528. PubMed ID: 31598919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
    Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD.
    Caussy C; Hsu C; Singh S; Bassirian S; Kolar J; Faulkner C; Sinha N; Bettencourt R; Gara N; Valasek MA; Schnabl B; Richards L; Brenner DA; Hofmann AF; Loomba R
    Aliment Pharmacol Ther; 2019 Jan; 49(2):183-193. PubMed ID: 30506692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19.
    Forlano R; Mullish BH; Mukherjee SK; Nathwani R; Harlow C; Crook P; Judge R; Soubieres A; Middleton P; Daunt A; Perez-Guzman P; Selvapatt N; Lemoine M; Dhar A; Thursz MR; Nayagam S; Manousou P
    PLoS One; 2020; 15(10):e0240400. PubMed ID: 33031439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.